Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listMYCOPHENOLATE SODIUM

MYCOPHENOLATE SODIUM

MYCOPHENOLATE SODIUM Structural

What is MYCOPHENOLATE SODIUM?

Description

Mycophenolate sodium, an immunosuppressive agent, was launched in Switzerland as an oral treatment in combination with Neoral? and corticosteroids for the prevention of acute transplant rejection in adult patients receiving allogeneic renal transplantation. In contrast to the previously marketed product mycophenolate mofetil (MMF, CellCept?), which is a prodrug and must be converted to mycophenolic acid (MPA) in vivo, Myfortic? contains MPA itself as the active ingredient. Myfortic? was designed to enhance the therapeutic efficacy of MPA through increased tolerability relative to systemic exposure. Unlike MMF, which is absorbed in the stomach, the enteric-coated formulation of MPA sodium is mainly absorbed in the small intestine, thus protecting the upper GI tract from the side effects of MPA. MPA is an inhibitor of inosine monophosphate dehydrogenase (IMDPH), a vital enzyme in the de novo pathway of purine biosynthesis. Proliferating lymphocytes rely principally on this pathway for purine production,thus rendering them succeptible to depletion of purine bases by MPA. Inhibition of IMPDH by MPA results in the inhibition of both T- and B-lymphocyte proliferation upon antigen challenge and facilitates the prevention of acute graft rejection. Following oral administration of MPA sodium, the tmax of MPA is 1.5–2 h, with a mean absolute bioavailability of 71% and a mean half-life of 11.7 h. MPA is primarily metabolized in the liver by glucuronidation and excreted mainly in the urine as the metabolite. The recommended dosage regimen of MPA sodium is 720 mg twice daily, which provides equimolar amounts of MPA compared with MMF 1000 mg twice daily. In two major clinical trials in 748 patients, Myfortic? was demonstrated to be a highly potent and well-tolerated immunosuppressant for new renal transplant patients. A trend was seen towards fewer dose reductions due to GI intolerability and less serious infections relative to other MPA drugs. The most common adverse events associated with MPA treatment are diarrhea and leukopenia.

Originator

Novartis (Switzerland)

The Uses of MYCOPHENOLATE SODIUM

Immunosuppressant

The Uses of MYCOPHENOLATE SODIUM

Mycophenolic Acid Monosodium Salt in its enteric-coated form is used as an immunosuppressive agent in organ transplantation and autoimmune diseases.Environmental contaminants; Food contaminants

Definition

ChEBI: An organic sodium salt that is the sodium salt of mycophenolic acid. An immunosuppressant, it is widely used to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.

brand name

Myfortic

Synthesis

Mycophenolic acid (137) was originally synthesized by Birch and Wright and has been the subject of several total and formal syntheses. The large production in industry is done via fermentation. A concise synthesis of mycophenolic acid published recently is depicted in Scheme 17. Reaction of dimethyl 1,3-acetonedicarboxylate (128) with commercially available geranyl chloride (129) in the presence of NaH gave ketoester 130 in 82% yield. Treatment of ketoester 130 with 4-(pivolyloxy)-2-butynal (131) in the presence of NaH provided resorcinol 132 in a single step with all substituents in place in 33% yield along with two more compounds represented by 133 (62%). Resorcinol 132 was transformed into 134 via a four step sequences: methylation with NaH and MeI in dry DMF, reduction of the formyl group with NaBH4, mesylation of the resulting alcohol and subsequent reduction of the mesylate. The preparation of phthalide 135 was affected in quantitative yield on treatment of 134 with K2CO3 in dry MeOH. Selective ozonolysis of compound 135, followed by Jones oxidation and esterification afforded ester 136. Demethylation with BCl3 in DCM followed by hydrolysis of the ester function gave the mycophenolic acid (137). The mycophenolic acid was then converted to its sodium salt XVII (no conditions and yield available£?.

Synthesis_37415-62-6

Safety information for MYCOPHENOLATE SODIUM

MYCOPHENOLATE SODIUM manufacturer

Solara Active Pharma Sciences Ltd

1Y
Phone:+91-7075706520
Whatsapp: +91 7075706520
product: 37415-62-6 Mycophenolate sodium 98%
Inquiry

Humble Healthcare Limited

1Y
Phone:+91-8006400378
Whatsapp: +91 8006400378
product: 37415-62-6 99%
Inquiry

BDR Pharmaceuticals International Pvt Ltd

1Y
Phone:+917718884418
Whatsapp: +91-7718884418
product: Mycophenolate sodium 98%
Inquiry

Rakshit Group of Companies (Rakshit Drugs Pvt Ltd)

1Y
Phone:+919246228579
Whatsapp: +91- 9246228579
product: Mycophenolate sodium 37415-62-6 98%
Inquiry

RPG Life Sciences Ltd

1Y
Phone:+91-2266606375
product: Mycophenolate sodium 99%
Inquiry

Concord Biotech Limited

1Y
Phone:+91-2714398200
product: Mycophenolate sodium 37415-62-6 98%
Inquiry

Samchem India

Delhi
Phone:91-8470038886
Whatsapp: 91-8470038886
product: Mycophenolate sodium
Inquiry

Pharma Links

Maharashtra
Phone:91-9619854045
Whatsapp: 91-9619854045
product: Mycophenolate sodium
Inquiry

Related products of tetrahydrofuran

You may like

Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.